Battle in Silicon Valley: Device makers trade barbs in the fight to gain share in robot assisted procedures

August 16, 2012 by Arezu Sarvestani

The best way to beat Intuitive Surgical out of the corner it has on the prostate cancer treatment market is by amping up the aggression, radiosurgery veteran and Varian chief medical officer John Adler tells

boxing gloves

Radiosurgery innovator and medtech veteran John Adler is ready for a fight.

The outspoken inventor of Accuray's (NSDQ:ARAY) CyberKnife system, as well as the company's founder and former CEO, Adler is an evangelist for radiosurgery and its potential in a variety of applications.

As chief medical officer for rival device maker Varian Medical (NYSE:VAR), Adler hopes to see radiosurgery companies push the envelope in fighting for mindshare among surgeons, especially in challenging Intuitive Surgical's (NSDQ:ISRG) da Vinci surgical robot, he told

Sign up to get our free newsletters delivered right to your inbox.

Adler is unabashedly enthusiastic about radiosurgery's future, which he views as limitless, albeit a bit sluggish to arrive. He's been actively watching the industry from Silicon Valley where Varian, Accuray and Intuitive Surgical's headquarters lie within a 10-mile radius.

"I would have thought where we are today we would have been 10 years ago, but nothing happens too fast in medicine," Adler said in an exclusive interview. "But it's unstoppable – radiosurgery is coming and it's going to change the world."

In order to do so, Adler added, radiosurgery players need to adopt a more aggressive strategy to engage surgeons, especially in urology and prostate cancer treatment where Intuitive Surgical has a strong presence.

"Radical prostatectomy's not a very good procedure, I don't care how you do it," Adler said. "It's certainly no better with the da Vinci."



Blame the medical device tax and the U.S. regulatory environment for the slump in investment in early-stage medical technologies, Silicon Valley Bank's Ben Johnson tells

Halyard Health, the publicly traded, $1.6 billion spinout of Kimberly-Clark's medical device business, is slated to go live in November, soon-to-be COO Chris Lowery tells

David Green tells about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years. brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.